This study looks at the long-term safety of a medicine called lonapegsomatropin used to treat children with Growth Hormone Deficiency (GHD), which means their body doesn't make enough growth hormone to grow properly. The study takes place in Europe and the USA where the medicine is already available. It is important because it helps us understand any possible safety risks when the medicine is used in real life.

Key Points:

• This study is for children already using lonapegsomatropin, not for those in other trials or using different growth hormone treatments.
• Participants must be willing to attend follow-up visits as required.
• The study does not include children with certain health issues like active cancer or those allergic to the medicine.